GlaxoSmithKline plc Q2 2025 Earnings Recap

GSK reported a robust Q2 2025 performance, with group sales up 6% and core operating profit increasing 12%, bolstered by strong contributions from Specialty Medicines and vaccines.

Key Takeaways

• Specialty Medicines drove a significant 15% sales growth, now accounting for 40% of total sales.
• Core earnings per share grew 15% to 46.5p, reflecting strong operational execution and effective cost management.
• GSK generated GBP 3.7 billion in cash in H1 2025, supporting shareholder returns and ongoing investments in R&D and pipeline expansion.
• The company remains on track to achieve top-end guidance for 2025 and projects long-term sales exceeding GBP 40 billion by 2031.
• Positive advancements in R&D, with three FDA approvals year-to-date, enabling accelerated pipeline development in specialty therapies.